Pharmacokinetics, pharmacodynamics, and safety of zoledronic acid in horses.

The research study is about testing the pharmacokinetics, pharmacodynamics, and safety of zoledronic acid in horses. The research suggests that zoledronic acid can be safely administered in horses without any adverse effects, indicating its potential utility in the treatment of orthopedic conditions in horses.

Methodology

• The study was conducted on 8 healthy horses. A single dose of zoledronic acid (0.057 mg/kg, IV) was administered for a thirty-minute period.
• The researchers collected venous blood at several intervals to measure zoledronic acid concentration in the plasma by liquid chromatography-tandem mass spectrometry. Through this, they managed to determine relevant pharmacokinetic parameters.
• The plasma was also analyzed for total calcium, BUN (Blood Urea Nitrogen), and creatinine concentrations. In addition, a particular marker for bone resorption, known as C-terminal telopeptides of type I collagen, was also assessed.

Results

• Zoledronic acid was safely administered intravenously during the thirty-minute period without any observed adverse effects.
• The plasma concentrations of zoledronic acid were found to be consistent with a 2-compartment mammillary model, visibly detectable up to 8 hours following administration.
• Following the introduction of zoledronic acid, the mean total calcium concentrations in plasma were found to be lower than the reference range seven days later.
• The bone resorption marker had a decline in concentration after the administration of zoledronic acid, remaining low for the entire one-year study duration.
• There were no noticeable changes in BUN and creatinine concentrations after administering zoledronic acid.

Conclusions

• Zoledronic acid was found to be safe for administration in healthy horses, with no observed adverse effects.
• These findings present zoledronic acid as the currently strongest bisphosphonate available. It prompts further evaluation into its potential benefits in horses suffering from orthopedic conditions.